ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary antibody-drug conjugate (ADC) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.
The US Food and Drug Administration (FDA) has granted orphan drug designation to ImmunoGen’s experimental ADC IMGN853 for the treatment of ovarian cancer.
Learn more about our pipeline.
ImmunoGen, Inc. one of The Boston Globe’s Top Places to Work 2014 – also recognized in 2013, 2011